Summit Therapeutics Inc
SMMT24.120USD
+0.500+2.12%
Fechamento 04/30, 16:00（ET）Cotações atrasadas em 15 min
17.79BValor de mercado
PerdaP/L TTM
Mais detalhes de Summit Therapeutics Inc Empresa
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Informações da empresa
Código da empresaSMMT
Nome da EmpresaSummit Therapeutics Inc
Data de listagemOct 14, 2004
Fundado em2020
CEODr. Mahkam (Maky) Zanganeh
Número de funcionários159
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 14
Endereço601 Brickell Key Drive
CidadeMIAMI
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal33131
Telefone13052032034
Sitehttps://www.smmttx.com/
Código da empresaSMMT
Data de listagemOct 14, 2004
Fundado em2020
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Latin America
0.00
0.00%
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
Estatísticas dos acionistas
Acionista
Proporção
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
Tipo
Acionista
Proporção
Individual Investor
84.90%
Investment Advisor
4.57%
Hedge Fund
4.06%
Investment Advisor/Hedge Fund
3.86%
Research Firm
0.40%
Pension Fund
0.02%
Bank and Trust
0.02%
Sovereign Wealth Fund
0.01%
Other
2.16%
Participação acionária institucional
Tempo de atualização: seg, 20 de jan
Tempo de atualização: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
403
717.89M
97.58%
+5.51M
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
2022Q4
154
191.34M
95.05%
+13.11M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Duggan (Robert William)
551.70M
74.81%
+3.33M
+0.61%
Sep 13, 2024
Zanganeh (Mahkam)
35.38M
4.8%
+84.32K
+0.24%
Apr 17, 2024
Xia (Yu)
31.52M
4.27%
--
--
Apr 17, 2024
Baker Bros. Advisors LP
24.42M
3.31%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
11.67M
1.58%
+724.04K
+6.61%
Dec 31, 2024
Fidelity Management & Research Company LLC
8.02M
1.09%
-277.94K
-3.35%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.55M
1.02%
+402.22K
+5.63%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.47M
0.88%
+1.11M
+20.72%
Dec 31, 2024
State Street Global Advisors (US)
5.60M
0.76%
+2.13M
+61.54%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.20M
0.43%
+101.04K
+3.26%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Tema Oncology ETF
2.77%
Invesco Nasdaq Biotechnology ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.42%
Range Cancer Immunotherapy ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.92%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.67%
Direxion Daily S&P Biotech Bull 3X Shares
0.58%
Simplify Next Intangible Core Index ETF
0.35%
Ver Mais
Tema Oncology ETF
Proporção2.77%
Invesco Nasdaq Biotechnology ETF
Proporção1.46%
ProShares Ultra Nasdaq Biotechnology
Proporção1.42%
Range Cancer Immunotherapy ETF
Proporção1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.04%
SPDR S&P Biotech ETF
Proporção0.92%
Invesco NASDAQ Next Gen 100 ETF
Proporção0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
Proporção0.67%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.58%
Simplify Next Intangible Core Index ETF
Proporção0.35%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados